Core Viewpoint - Oriental Bio's stock price has shown fluctuations, with a recent increase of 2.05% and a year-to-date decline of 6.75%, indicating potential volatility in the market [1] Financial Performance - For the period from January to September 2025, Oriental Bio reported a revenue of 672 million yuan, reflecting a year-on-year growth of 2.16% [2] - The company experienced a net profit attributable to shareholders of -213 million yuan, which is an improvement of 18.89% compared to the previous period [2] Shareholder Information - As of September 30, 2025, the number of shareholders for Oriental Bio was 13,300, a decrease of 3.93% from the previous period [2] - The average number of circulating shares per shareholder increased by 4.09% to 15,170 shares [2] Dividend Distribution - Since its A-share listing, Oriental Bio has distributed a total of 1.607 billion yuan in dividends, with 336 million yuan distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, the fourth largest circulating shareholder is Rongtong Health Industry Flexible Allocation Mixed A/B, holding 2.8 million shares, a decrease of 1.7001 million shares from the previous period [3] - Hong Kong Central Clearing Limited is the sixth largest shareholder, increasing its holdings by 139,400 shares to 1.4675 million shares [3] - The Southern Science and Technology Innovation Board 3-Year Open Mixed Fund maintained its holding of 780,900 shares, while the Medical Device ETF entered as a new shareholder with 757,900 shares [3]

安序源科技* Axbio International Limited （「本公司」） （於開曼群島註冊成立的有限公司） 的申請版本 香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責， 對其準確性或完整性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部 分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的。投資者不 應根據本文件所載資料作出任何投資決定； (b) 在 聯 交 所 網 站 登 載 本 文 件 或 其 補 充、修 訂 或 更 換 附 頁，不 會 引 致 本 公 司、其 聯 席 保 薦人、整體協調人、顧問或包銷團成員須在香港或任何其他司法管轄區進行發售活 動的責任。本公司最終會否進行發售仍屬未知之數； (c) 本文件或其補充、修訂或更換附頁的內容可能會亦可能不會在實際最終的上市文件 內全部或部分轉載； (d) 本申請版本並非最終的上市文件，本公司可能不時根據香港聯合交易所有限公司證 券上市規則作出更新或修訂； (e) 本文件並不構成向任何司法管轄區的公眾人士提呈出售任何證券的招股章程、發售 ...

Core Viewpoint - Meinian Health's stock price has shown a year-to-date increase of 20.60%, despite a recent decline of 2.99% over the last five trading days, indicating volatility in the market [1][2]. Financial Performance - For the period from January to September 2025, Meinian Health reported a revenue of 6.925 billion yuan, reflecting a year-on-year decrease of 3.01%. However, the net profit attributable to shareholders increased significantly by 110.53% to 51.86 million yuan [2]. - Cumulatively, Meinian Health has distributed 634 million yuan in dividends since its A-share listing, with 127 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Meinian Health was 152,000, a decrease of 11.85% from the previous period. The average number of circulating shares per person increased by 13.44% to 25,490 shares [2]. - The top ten circulating shareholders include notable entities such as Huabao Zhongzheng Medical ETF and Nanfang Zhongzheng 500 ETF, with the former reducing its holdings by 15.12 million shares [3]. Market Activity - On November 10, Meinian Health's stock price reached 5.52 yuan per share, with a trading volume of 348 million yuan and a turnover rate of 1.65%. The total market capitalization stood at 21.607 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" twice this year, with the most recent instance on February 19, where it recorded a net buy of -155 million yuan [1].

Core Viewpoint - Anke Biological has shown a mixed performance in stock price and financial results, with a notable increase in stock price year-to-date but a decline in net profit for the recent period [1][2]. Financial Performance - As of October 31, Anke Biological reported a revenue of 1.963 billion yuan for the period from January to September 2025, representing a year-on-year growth of 2.15%. However, the net profit attributable to shareholders was 551 million yuan, which reflects a decrease of 6.48% compared to the previous year [2]. - The company has cumulatively distributed 2.662 billion yuan in dividends since its A-share listing, with 1.252 billion yuan distributed over the last three years [3]. Stock Market Activity - On November 7, Anke Biological's stock price increased by 2.06%, reaching 10.91 yuan per share, with a trading volume of approximately 90.89 million yuan and a turnover rate of 0.69%. The total market capitalization stood at 18.247 billion yuan [1]. - Year-to-date, the stock price has risen by 30.02%, with a slight increase of 5.72% over the past 20 trading days [1]. Shareholder Structure - As of September 30, 2025, Anke Biological had 76,900 shareholders, an increase of 4.63% from the previous period. The average number of circulating shares per shareholder decreased by 4.43% to 15,886 shares [2]. - The top ten circulating shareholders include significant institutional investors, with Hong Kong Central Clearing Limited holding 19.5226 million shares, a decrease of 1.269 million shares from the previous period [3].

Core Viewpoint - Guangshentang's stock price has shown significant volatility, with a year-to-date increase of 231.65%, but recent performance indicates a slight decline in the short term [1][2]. Group 1: Stock Performance - As of November 6, Guangshentang's stock price rose by 2.02% to 108.35 CNY per share, with a trading volume of 6.42 billion CNY and a turnover rate of 4.41%, resulting in a total market capitalization of 17.257 billion CNY [1]. - The stock has experienced a 1.40% decline over the last five trading days, a 14.05% increase over the last 20 days, and a 6.15% decline over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" four times this year, with the most recent appearance on July 31 [1]. Group 2: Financial Performance - For the period from January to September 2025, Guangshentang reported a revenue of 316 million CNY, reflecting a year-on-year decrease of 3.21%, and a net profit attributable to shareholders of -112 million CNY, a decline of 57.96% year-on-year [2]. - The company has cumulatively distributed dividends of 84.6485 million CNY since its A-share listing, with no dividends paid in the last three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Guangshentang increased to 45,800, a rise of 125.95%, while the average number of tradable shares per shareholder decreased by 55.74% to 2,985 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the seventh largest with 1.7463 million shares, marking its entry as a new shareholder [3].

Group 1 - The core viewpoint of the news is that Kaineng Health has shown a positive stock performance with a year-to-date increase of 13.58% and a recent uptick of 2.09% in stock price, indicating investor confidence [1][2] - As of November 6, Kaineng Health's stock price is reported at 6.85 CNY per share, with a market capitalization of 4.189 billion CNY and a trading volume of 71.29 million CNY [1] - The company has experienced a net inflow of main funds amounting to 9.423 million CNY, with significant buying activity from large orders [1] Group 2 - For the period from January to September 2025, Kaineng Health achieved operating revenue of 1.356 billion CNY, reflecting a year-on-year growth of 8.10%, and a net profit attributable to shareholders of 95.3532 million CNY, up 13.29% year-on-year [2] - Kaineng Health has distributed a total of 694 million CNY in dividends since its A-share listing, with 283 million CNY distributed over the past three years [3] Group 3 - Kaineng Health's main business involves the research, manufacturing, sales, and service of health-related water products for both residential and commercial use, with revenue composition being 61.31% from terminal business and services, and 37.24% from intelligent manufacturing and core components [1] - The company is categorized under the household appliances industry, specifically in small appliances and cleaning small appliances, and is associated with concepts such as small-cap stocks, gene sequencing, wastewater treatment, energy conservation, and medical beauty [1]

Core Viewpoint - The stock of Aide Biological has shown a modest increase, with a current price of 23.30 CNY per share and a market capitalization of 9.123 billion CNY, reflecting a stable performance in the medical diagnostics sector [1]. Financial Performance - For the period from January to September 2025, Aide Biological reported a revenue of 866 million CNY, representing a year-on-year growth of 2.08%, while the net profit attributable to shareholders was 263 million CNY, marking a 15.50% increase compared to the previous year [2]. - The company has distributed a total of 421 million CNY in dividends since its A-share listing, with 232 million CNY distributed over the last three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Aide Biological increased to 26,600, up by 5.23%, while the average number of circulating shares per person decreased by 4.97% to 14,628 shares [2]. - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 35.3892 million shares, an increase of 3.7186 million shares from the previous period [3]. Stock Performance - Aide Biological's stock has increased by 3.56% year-to-date, with a 1.48% rise over the last five trading days and a 3.74% increase over the last 20 days, although it has seen a decline of 1.81% over the past 60 days [1]. Business Overview - Aide Biological, established on February 21, 2008, and listed on August 2, 2017, specializes in the research, production, and sales of molecular diagnostic products for precision oncology, with a revenue composition of 83.43% from testing reagents, 9.84% from clinical research services, and 5.61% from testing services [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in medical devices and in vitro diagnostics, and is associated with concepts such as gene sequencing and precision medicine [1].

Core Viewpoint - Meinian Health's stock price has shown significant growth this year, with a year-to-date increase of 25.63% and notable short-term gains in recent trading days [2] Group 1: Stock Performance - As of November 3, Meinian Health's stock price reached 5.75 CNY per share, with a trading volume of 5.98 billion CNY and a market capitalization of 225.07 billion CNY [1] - The stock has experienced a 2.13% increase during intraday trading on November 3 [1] - Year-to-date, the stock has risen by 25.63%, with increases of 11.22% over the last five trading days, 15.93% over the last 20 days, and 10.15% over the last 60 days [2] Group 2: Financial Performance - For the period from January to September 2025, Meinian Health reported a revenue of 6.925 billion CNY, reflecting a year-on-year decrease of 3.01%, while the net profit attributable to shareholders was 51.86 million CNY, showing a year-on-year increase of 110.53% [2] - The company has distributed a total of 634 million CNY in dividends since its A-share listing, with 127 million CNY distributed over the past three years [3] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Meinian Health was 152,000, a decrease of 11.85% from the previous period, with an average of 25,490 circulating shares per shareholder, an increase of 13.44% [2] - The top ten circulating shareholders include Huabao Zhongzheng Medical ETF and Nanfang Zhongzheng 500 ETF, with the former holding 88.66 million shares and the latter being a new entrant with 45.63 million shares [3]

Group 1 - The core viewpoint of the news is that Guofa Co., Ltd. has shown a mixed performance in its stock price and financial results, with a notable increase in stock price recently but a decline in revenue year-on-year [1][2]. Group 2 - As of November 3, Guofa's stock price increased by 2.09% to 5.87 CNY per share, with a total market capitalization of 3.077 billion CNY [1]. - The company has seen a year-to-date stock price increase of 13.76%, with a 3.89% increase over the last five trading days and a 5.58% increase over the last twenty days, while it has decreased by 9.69% over the last sixty days [1]. - The main business revenue composition includes 62.69% from pharmaceutical distribution, 22.39% from DNA testing equipment and services, 8.38% from pharmaceutical manufacturing, 6.28% from judicial identification, and 0.26% from other sources [1]. Group 3 - As of September 30, the number of shareholders for Guofa was 19,100, a decrease of 0.13% from the previous period, with an average of 27,403 circulating shares per shareholder, an increase of 0.13% [2]. - For the period from January to September 2025, Guofa reported operating revenue of 239 million CNY, a year-on-year decrease of 9.26%, while the net profit attributable to the parent company was -3.85 million CNY, an increase of 81.56% year-on-year [2]. Group 4 - Since its A-share listing, Guofa has cumulatively distributed 11.08 million CNY in dividends, with no dividends distributed in the last three years [3].

Core Viewpoint - Yuheng Pharmaceutical is a well-known chemical formulation enterprise in China, with strong competitiveness in drug production and agency sales, and a rich product line and professional marketing team [1] Group 1: Business Performance - In Q3 2025, Yuheng Pharmaceutical reported revenue of 1.665 billion yuan, ranking 39th among 110 companies in the industry, while the industry leader, Huadong Medicine, had revenue of 32.664 billion yuan [2] - The net profit for the same period was 248 million yuan, placing the company 30th in the industry, with the top performer, Heng Rui Medicine, achieving a net profit of 5.76 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Yuheng Pharmaceutical's debt-to-asset ratio was 28.13%, down from 32.28% year-on-year, which is lower than the industry average of 35.26%, indicating improved debt repayment capability [3] - The gross profit margin for Q3 2025 was 46.42%, down from 53.25% year-on-year, and below the industry average of 57.17%, suggesting a need for improvement in profitability [3] Group 3: Management Team - The chairwoman, Shen Zhenyu, has a rich background and has held various leadership positions, while the general manager, Guo Leifeng, has extensive experience in investment management [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 2.99% to 102,500, while the average number of circulating A-shares held per shareholder increased by 3.08% to 20,400 [5] - The top circulating shareholder, Hong Kong Central Clearing Limited, increased its holdings by 35.136 million shares [5] Group 5: Future Outlook - Tianfeng Securities has adjusted its revenue forecasts for 2025-2027 to 2.364 billion, 2.464 billion, and 2.661 billion yuan, while raising net profit forecasts to 258 million, 282 million, and 318 million yuan for the same period [5] - First Capital Securities expects revenues of 2.437 billion, 2.751 billion, and 3.08 billion yuan, with net profits of 256 million, 291 million, and 328 million yuan for 2025-2027 [6]